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Supplementary Appendix
Design and Methods
Statistics
The effects of the following prognostic factors on objective response, best response, and on overall survival were analyzed: gender, age (<75, ≥75 years), performance status (ECOG 0, 1, 2+3), comorbidity index 1 (0, 1-2, ≥3), French-American-British subtype (M6, no M6), cytogenetics (favorable/intermediate, adverse, no metaphases/not assessed), 2 presence or absence of monosomal karyotype, 3 prior myelodysplastic syndrome (no, yes), white blood cell count (<5, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .99, 20-49.99, ≥50 x 10 9 /L), platelets (<50, ≥50¥10 9 /L), serum lactate dehydrogenase (<300, ≥300 U/L), hemoglobin (<10, ≥10 g/dL), bone marrow blasts (<50, ≥50%). The categorization of the factors was predefined independent of outcome. The effects of the factors were first analyzed in univariate analyses. Factors showing an effect with a P-value below 0.1 were included in multivariate analyses. In addition, the effects of two recently published prognostic scores from the MRC (the Wheatley score 4 ) and ALFA (Malfuson score   5 ) groups were analyzed. Both are used to predict the outcome of older acute myeloid leukemia patients in response to treatment: the Wheatley score applies the five parameters cytogenetic group, age, white blood cell count, performance status and type of acute myeloid leukemia (de novo, secondary), the Malfuson score applies the four parameters unfavorable cytogenetics, age ≥75 years, performance status ≥2, and white blood cell count ≥50¥10 9 /L. A more detailed analysis of the effect of duration of prior myelodysplastic syndrome was conducted in 109 patients with prior myelodysplastic syndrome of known duration. The effects of monosomal and complex karyotype were analyzed in 120 patients with abnormal cytogenetics.
Online Supplementary Table S1 . Specification of infections captured by comorbidity scoring according to Sorror et al. Online Supplementary Table S2 . Reasons for ineligibility for induction therapy, as determined at study entry by the treating physician. Low performance status, higher age and significant comorbidities were not further specified. 
Requiring antimicrobial treatment n=51
All (n=227)(%) <75 years (n=140) (%) ≥ 75 years (n=87) (%)
